Impedimed

About the author:

Author name:

By Scott Power

Job title:

Senior Analyst

Date posted:

22 April 2014, 10:40 AM

Sectors Covered:

Healthcare, Life Sciences

Impedimed (IPD) has released its quarterly cashflow statement. Highlights are as follows:

• Continued sales growth with L-Dex sales at A$343k and revenue of A$887k for the quarter.
• Operating cash burn was A$1.35m.

The completion of the A$8.8m placement takes the funding question off the table. Anticipated key milestone for IPD will be Medicare reimbursement and the Category 1CTP code which comes into effect on 1 January 2015.

Impedimed's Share Purchase Plan (SPP) closes this Thursday (24 April). We recommend taking up the offer at A$0.195.

More information

Morgans clients can access our detailed research report on Impedimed (IPD). If you are interested in finding out more, please contact your nearest Morgans office.

Disclaimer(s): Morgans is the Manager of the SPP and will earn fees in this regard.

Analyst owns shares.

The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.